GLP-1 for PCOS: What the Clinical Evidence Shows (2026 Update)

Polycystic ovary syndrome (PCOS) affects roughly one in ten women of reproductive age. Despite being one of the most common endocrine conditions in women, the medication options have been narrow for decades — combined oral contraceptives for cycle and androgen control, metformin for insulin resistance, spironolactone for hirsutism. None of those medications address the full picture, and none of them produce meaningful weight loss in the patients who need it.

GLP-1 receptor agonists changed that calculus. Since 2022, the PCOS-specific evidence base for semaglutide and tirzepatide has compounded fast. By the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — the global standard-of-care document co-published by ESHRE, the Endocrine Society, the ASRM, and the Monash Centre for Health Research — GLP-1 was formally recognized as an option for weight management in women with PCOS who have not responded sufficiently to lifestyle intervention. That guideline shifted GLP-1 from off-protocol to inside the international PCOS standard.

This post summarizes what the evidence shows, where the gaps remain, and how clinicians are using GLP-1 in PCOS practice today.

The metabolic mechanism

PCOS is defined clinically by the Rotterdam criteria — a combination of irregular cycles, biochemical or clinical hyperandrogenism, and polycystic ovarian morphology. The diagnostic criteria are heterogeneous, but the underlying mechanism in the majority of cases is consistent: insulin resistance.

Insulin and insulin-like growth factor 1 (IGF-1) signal directly on ovarian theca cells. When circulating insulin is chronically elevated — which is the metabolic profile of most women with PCOS, especially those carrying additional weight — theca-cell androgen synthesis is pushed up. At the same time, hyperinsulinemia suppresses hepatic production of sex-hormone binding globulin (SHBG), which raises free testosterone and amplifies the phenotype. The downstream effects are familiar to anyone who has lived with PCOS: irregular ovulation, hirsutism, acne, weight retention concentrated in the abdomen, and metabolic markers that drift over the years toward prediabetes and type 2.

Address the insulin resistance and the cascade downstream tends to improve. That is why metformin has been in PCOS care for decades, and why even modest weight loss — 5 to 10 percent of body weight — has been shown to restore ovulation in many PCOS patients in landmark lifestyle trials.

GLP-1 receptor agonists work both arms at once. They improve insulin sensitivity directly through central and peripheral mechanisms, and they produce clinically meaningful weight loss through appetite reduction and slowed gastric emptying. The combination is unusually well-matched to PCOS pathophysiology — more so than metformin alone, which improves insulin sensitivity but does little for weight.

The clinical evidence

The longest evidence base for GLP-1 in PCOS is for liraglutide — a daily GLP-1 receptor agonist that was the first in the class to be widely used clinically. Multiple randomized trials between 2014 and 2020 showed that liraglutide in PCOS women produced significant weight loss, reduced HOMA-IR, lowered free androgen index, and improved menstrual regularity. The signal was consistent across studies.

Semaglutide accelerated the evidence base. The Jensterle 2023 trial (Diabetes, Obesity & Metabolism) randomized 30 women with PCOS and obesity to weekly semaglutide 1.0 mg or placebo for 16 weeks. The semaglutide arm showed significant reductions in androstenedione and free testosterone, plus the gastric-emptying delay (37% solid retention at four hours, vs. 0% placebo) that is now relevant to oral-contraceptive absorption guidance in this population. Subsequent semaglutide trials and real-world cohorts have consistently reported 10 to 15 percent weight loss at six months, large drops in HOMA-IR, decreased free androgen index, and meaningful improvements in cycle regularity. A 2025 RCT (n=100, 16 weeks) reported that semaglutide added to metformin produced greater weight loss, lower fasting insulin and HOMA-IR, and a higher natural pregnancy rate than metformin alone — one of the first PCOS trials to report a hard reproductive outcome.

The biggest single dataset to date is the UK real-world tirzepatide cohort: 4,241 women with PCOS prescribed tirzepatide between February 2024 and January 2025. Median weight loss was 18.81% at ten months, with 90.8% of women losing at least 10% of body weight and 75.96% losing at least 15%. A separate Bangladesh observational cohort (2025) reported a 9.54% mean weight reduction over similar timeframes. The PCOS-specific tirzepatide dataset is still smaller than the semaglutide one, but the magnitude of effect is consistent with what tirzepatide produces in the general weight-loss population — and on PCOS-relevant secondary endpoints (insulin, androgens, cycles), the early reports track the semaglutide pattern at larger scale.

Meta-analyses through late 2024 — including Cena et al. in five pooled PCOS trials — have estimated the average effect sizes across studies: approximately 28% reduction in free testosterone, approximately 68% improvement in menstrual regularity, and approximately 31% improvement in HOMA-IR, with ovulation rates rising about 55% — and the largest improvements concentrated in patients who lost at least 10% of body weight. The Abdalla et al. systematic review (European Journal of Endocrinology, 2026) of 11 RCTs through September 2024 reported a pooled BMI reduction of −1.38 kg/m² versus control. The signal is consistent across the literature, and it is the right direction on every endpoint that matters in PCOS.

The 2023 International Evidence-Based Guideline reviewed this evidence base and conditionally recommended GLP-1 receptor agonists as an option for weight management in women with PCOS who have not responded to lifestyle intervention. The guideline is careful: GLP-1 is not first-line, lifestyle remains the foundation, and contraception counseling is required for any reproductive-age woman on therapy. But it formally moved GLP-1 from off-protocol to inside the international standard. The Society for Endocrinology's Summer 2025 editorial — "Can PCOS Be Treated with GLP-1 Receptor Analogues?" — went further and affirmed the emerging clinical role of the medication class in PCOS practice.

What the evidence does not yet show

The PCOS evidence base for GLP-1 is strong on metabolic and intermediate endpoints — weight, HOMA-IR, androgens, cycle regularity. It is thinner on hard fertility outcomes.

Specifically: large, dedicated, head-to-head trials of GLP-1 versus other PCOS interventions with live-birth outcomes are still scarce. Most of the fertility-relevant signal in the published literature is on ovulation rate and cycle regularity — both reasonable proxies, but proxies. Patients trying to conceive in the near term should know that the evidence supports GLP-1 as a metabolic and weight-management tool that can improve fertility precursors, but not as a fertility medication per se. And GLP-1 medications are not used during conception or pregnancy — they require washout.

The dataset is also thinner for adolescents and for women with normal-weight PCOS (sometimes called "lean PCOS"). Most trials have enrolled patients with overweight or obesity. The mechanism is the same, but the clinical reasoning for dose selection in lean PCOS is different — microdose protocols are often more appropriate when significant weight loss is not the goal.

Fertility timing — the most important conversation

For PCOS patients who are or will be trying to conceive, the protocol gets planned around the fertility window, not the other way around.

Current labeling guidance for semaglutide is to discontinue the medication at least two months before a planned pregnancy. The guidance for tirzepatide is similar. The reason: there is not enough human pregnancy safety data, and animal studies have raised concerns about embryo-fetal effects. Until larger human safety datasets accumulate, the consensus position is to wash out before TTC.

This produces a common and appropriate sequence in PCOS practice: a patient with weight to lose and cycles to restore goes on GLP-1, loses weight and recovers regular cycles over six to twelve months, then washes out for two to three months before starting to try to conceive. The metabolic improvements persist for some time after stopping, and the cycle regularity gained during therapy often persists into the TTC window. If pregnancy does not happen, GLP-1 can be restarted after delivery and breastfeeding.

This sequence is not the only valid one — clinicians plan around individual circumstances — but it is the most common path.

How GLP-1 fits with metformin and inositol

Metformin and myo-inositol both improve insulin sensitivity through different mechanisms than GLP-1. They are not exclusive with GLP-1, and many PCOS patients stack them.

Metformin works peripherally on hepatic glucose production and skeletal-muscle insulin signaling. Inositol — particularly the myo-inositol and D-chiro-inositol stack — appears to act through intracellular insulin signaling cascades. GLP-1 acts centrally on appetite and peripherally on insulin secretion and tissue sensitivity. Stacking the three is mechanistically reasonable and is commonly done in clinical practice, though large RCTs of three-medication combinations are limited.

The clinician's decision on what to combine is individualized: a patient with mild insulin resistance and a strong response to inositol may not need GLP-1; a patient with severe insulin resistance, significant weight, and a long history of failed lifestyle intervention may benefit from all three. There is no one-size protocol.

Who GLP-1 is and is not for in PCOS

Good candidates for GLP-1 in PCOS typically share these features:

• A PCOS diagnosis (or are working toward one with a clinician).
• Weight or insulin resistance is part of the clinical picture.
• Lifestyle intervention alone has not produced sufficient metabolic improvement.
• Not currently pregnant, breastfeeding, or actively TTC within the next 2-3 months.
• No contraindications (medullary thyroid carcinoma history, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, prior pancreatitis).

Patients who are TTC in the near term, who are pregnant or breastfeeding, who have a personal or family history of medullary thyroid carcinoma, or who have any of the standard GLP-1 contraindications are not candidates.

For patients with lean PCOS (normal BMI, biochemical hyperandrogenism, and metabolic irregularity), the calculus is more nuanced — significant weight loss is not the goal, so the clinician weighs whether a microdose protocol is appropriate to capture the insulin-sensitizing effect without producing unnecessary weight reduction.

What we do at TelePeptide

The PCOS protocol uses the same compounded GLP-1 medications as our standard programs — semaglutide and tirzepatide — with the clinical reasoning adjusted for the PCOS context. The clinician reviews insulin markers (HOMA-IR, fasting insulin, A1c), androgen markers (free testosterone, DHEA-S, SHBG), and cycle history alongside weight when deciding on medication and dose.

We do not promise cycle restoration, ovulation, or any specific fertility outcome. What we do is run a clinician-supervised metabolic protocol that addresses the underlying driver of PCOS — insulin resistance and weight — and let the downstream effects follow. Patients with TTC plans get those plans built into the protocol from intake. The medication is not used during pregnancy or breastfeeding.

Compounded medications are prepared by licensed 503A pharmacies and are not FDA-approved.

---

Sources & further reading. The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (Teede et al., Monash University) is the single most useful document for understanding where GLP-1 sits in current PCOS care. Individual trial reports for semaglutide and tirzepatide in PCOS are now appearing across the endocrinology and reproductive-medicine literature — your clinician can point you to the most relevant ones for your situation.

This article is for education, not medical advice. Whether GLP-1 is appropriate for your PCOS depends on your individual clinical picture. The decision is made by you and a licensed clinician, based on your full history.